Aug 26, 2009

Thrombotic events in patients with cancer receiving antiangiogenesis agents

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Maurizio ZangariGuido Tricot

Abstract

Tumor-associated neoangiogenesis has recently become a suitable target for antineoplastic drug development. In this overview, we discuss specific drug-associated hemostatic complications, the already known pathogenetic mechanisms involved, and the effect of varying antithrombotic strategies. Multiple agents with angiogenic inhibitory capacity (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib, and sirolimus) have obtained US Food and Drug Administration approval, and many others have entered clinical trials. Arterial and venous thromboembolism and hemorrhage have emerged as significant toxicities associated with the use of angiogenesis inhibitors. We present a detailed analysis of the literature on thrombotic complication of antiangiogenic drugs. Close attention to hemostatic complications during antiangiogenic treatment is warranted. Further studies are required to better understand the pathophysiologic mechanisms involved and to define a safe prophylactic strategy.

  • References97
  • Citations86

References

  • References97
  • Citations86

Mentioned in this Paper

Lenalidomide
Angiogenic Process
Vascular Hemostatic Disorders
Venous Thromboembolism
Sorafenib
Survival Analysis
Hemostatic Agents
Thromboembolism
Pathologic Neovascularization
Thalidomide

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Toni K ChoueiriJoaquim Bellmunt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Anna Falanga, Marina Marchetti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Gary H LymanAmerican Society of Clinical Oncology
© 2020 Meta ULC. All rights reserved